GLP-1 Weight Loss Guide

    The Complete Guide to GLP-1 Medications

    Everything you need to know about semaglutide, tirzepatide, and other weight loss medications. Evidence-based information to help you make informed decisions about your health.

    Explore the Guide

    What Are GLP-1 Medications?

    GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications originally developed for type 2 diabetes that have shown remarkable effectiveness for weight loss. They work by mimicking a natural hormone that regulates appetite, blood sugar, and digestion.

    When you eat, your body naturally releases GLP-1, which signals to your brain that you're full. These medications amplify that signal, leading to reduced appetite, slower gastric emptying, and ultimately significant weight loss.

    The two main medications in this class are Semaglutide (brand names: Ozempic, Wegovy, Rybelsus) and Tirzepatide (brand names: Mounjaro, Zepbound). Tirzepatide is a dual GIP/GLP-1 agonist, targeting two hormones for potentially greater effects.

    How Do They Work?

    • Appetite Suppression: Signals satiety to the brain, reducing hunger and food cravings
    • Slower Digestion: Delays gastric emptying, keeping you fuller longer after meals
    • Blood Sugar Control: Stimulates insulin release and reduces glucagon in response to meals
    • Reduced "Food Noise": Many users report decreased obsessive thoughts about food

    Key Benefits

    Significant Weight Loss

    15-25% body weight reduction with consistent use

    Cardiovascular Benefits

    Reduced risk of heart attack and stroke

    Metabolic Improvements

    Better blood sugar control and insulin sensitivity

    Reduced Appetite

    Natural hunger suppression and food noise reduction

    Who Is a Candidate?

    GLP-1 medications are FDA-approved for specific patient populations. While they've shown remarkable results, they're not appropriate for everyone. Here are the typical criteria for candidacy:

    • BMI of 30 or higher (obesity)
    • BMI of 27+ with weight-related conditions (diabetes, hypertension, sleep apnea)
    • Previous unsuccessful attempts at diet and exercise alone
    • No personal or family history of medullary thyroid carcinoma
    • No history of pancreatitis or severe GI conditions
    • Not pregnant, breastfeeding, or planning pregnancy

    Expected Results

    Semaglutide (Wegovy)~15% body weight
    Tirzepatide (Zepbound)~21% body weight
    Timeline12-18 months

    *Results from clinical trials at maximum doses with diet and exercise

    Cost Overview

    MedicationBrand (Cash)CompoundedWith Insurance
    Wegovy (Semaglutide)$1,350/mo$150-300/mo$25-150/mo
    Zepbound (Tirzepatide)$1,060/mo$200-400/mo$25-150/mo
    Ozempic (Semaglutide)$970/mo$150-300/mo$25-100/mo
    Mounjaro (Tirzepatide)$1,070/mo$200-400/mo$25-150/mo

    Popular Providers

    Frequently Asked Questions

    Ready to Get Started?

    Compare medications to find the right fit, learn about proper dosing, or connect with a licensed provider who can evaluate your candidacy.